- Home
- LXFR vs NGNE Comparison
LXFR vs NGNE Comparison
Compare LXFR & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXFR
- NGNE
- Stock Information
- Founded
- LXFR 1898
- NGNE 2003
- Country
- LXFR United States
- NGNE United States
- Employees
- LXFR N/A
- NGNE N/A
- Industry
- LXFR Major Chemicals
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- LXFR Industrials
- NGNE Health Care
- Exchange
- LXFR Nasdaq
- NGNE Nasdaq
- Market Cap
- LXFR 335.4M
- NGNE 325.3M
- IPO Year
- LXFR 2012
- NGNE N/A
- Fundamental
- Price
- LXFR $13.42
- NGNE $18.48
- Analyst Decision
- LXFR
- NGNE Strong Buy
- Analyst Count
- LXFR 0
- NGNE 7
- Target Price
- LXFR N/A
- NGNE $41.86
- AVG Volume (30 Days)
- LXFR 135.6K
- NGNE 110.1K
- Earning Date
- LXFR 10-28-2025
- NGNE 08-11-2025
- Dividend Yield
- LXFR 3.87%
- NGNE N/A
- EPS Growth
- LXFR N/A
- NGNE N/A
- EPS
- LXFR 0.90
- NGNE N/A
- Revenue
- LXFR $403,800,000.00
- NGNE N/A
- Revenue This Year
- LXFR $3.12
- NGNE N/A
- Revenue Next Year
- LXFR $3.31
- NGNE N/A
- P/E Ratio
- LXFR $13.74
- NGNE N/A
- Revenue Growth
- LXFR 5.60
- NGNE N/A
- 52 Week Low
- LXFR $9.41
- NGNE $6.88
- 52 Week High
- LXFR $15.64
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- LXFR 64.00
- NGNE 35.93
- Support Level
- LXFR $12.32
- NGNE $19.59
- Resistance Level
- LXFR $13.86
- NGNE $20.46
- Average True Range (ATR)
- LXFR 0.45
- NGNE 1.23
- MACD
- LXFR 0.11
- NGNE -0.20
- Stochastic Oscillator
- LXFR 78.85
- NGNE 13.37
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.